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Background: Children with Down syndrome (DS) have increased risk of myeloid
leukemia (ML), but specific treatment protocols ensure excellent outcome. This study
was a retrospective analysis of the treatment results and genetic characteristics of ML of
DS (ML-DS) in Poland from 2005 to 2019.
Methods: All 54 patients with ML-DS registered in the Polish Pediatric Leukemia
and Lymphoma Study Group in analyzed period were enrolled to the study. There
were 34 children treated with Acute Myeloid Leukemia–Berlin-Frankfurt-Munster 2004
Interim Protocol (group I) and 20 patients treated with ML-DS 2006 Protocol (group
II). In the first protocol, there was reduction of the antracyclines doses and intrathecal
treatment for ML-DS compared to non-DS patients. In the second protocol, further
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reduction of the treatment was introduced (omission of etoposide in the last cycle, no
maintenance therapy).
Results: Probabilities of 5-year overall survival (OS), event-free survival (EFS), and
relapse-free survival in the whole analyzed group were 0.85 ± 0.05, 0.83 ± 0.05, and
0.97 ± 0.03, respectively. No significant differences were found between two protocols
in the terms of OS and EFS (0.79 ± 0.07 vs. 0.95 ± 0.05, p = 0.14, and 0.76 ± 0.07 vs.
0.95 ± 0.05, p = 0.12, respectively). All deaths were caused by the treatment-related
toxicities. Reduction of the treatment-related mortality was noticed (20% in group I and
5% in group II). The only one relapse in the whole cohort occurred in the patient from
group I, older than 4 years, without GATA1 gene mutation. He was treated successfully
with IdaFLA cycle followed by hematopoietic stem cell transplantation from matched
sibling donor. No significant prognostic factor was found in the study group probably
due to low number of patients in the subgroups.
Conclusions: The study confirms that the reduced intensity protocols are very effective
in ML-DS patients. The only cause of deaths was toxicities; however, systematic
decrease of the treatment-related mortality was noticed.
Keywords: myeloid leukemia, down syndrome, children, treatment results, genetic characteristics
INTRODUCTION
Children with Down syndrome (DS) have increased risk of
myeloid leukemia (ML) compared to children without DS (150-
fold before the age of 5 years) (1). Myeloid leukemia in DS
children (ML-DS) is characterized by several unique features.
Approximately 50% of patients are diagnosed within the first
year of life, and only 1–2% at 4 years or older (1). It shows a
high prevalence of the acute megakaryocytic leukemia phenotype
(AMKL), which is rare in non-DS acute myeloid leukemia (AML)
(2, 3). Myeloid leukemia of DS can be preceded by transient
abnormal myelopoiesis (TAM) observed in approximately 10%
of neonates with DS (4, 5). Approximately 20 to 30% of TAM
can progress to ML-DS (5, 6). Both TAM and ML-DS, especially
AMKL, are associated with mutations of the hematopoietic
transcription factor GATA1 (7–9). Development of ML-DS is
frequently preceded by myelodysplastic phase characterized by
thrombocytopenia and anemia. Myeloid neoplasms of DS are
not subclassified into myelodysplastic syndrome (MDS) or AML
because they have a similar behavior independently of blast cell
count (10). In case of evidence for leukemic blasts in the bone
marrow, it is recommended that children with DS should be
diagnosed with AML, even if the blast threshold of 20% is not
reached (11). According to the World Health Organization 2008
and 2016 classifications, bothMDS and AML in children with DS
are classified as a separate entity—ML of DS (ML-DS) (10, 12).
Myeloid blasts in children with DS have high drug sensitivity
especially to cytarabine and anthracyclines (13). That determines
excellent response to the treatment. The risk of the therapy-
associated toxicities is higher in children with DS compared to
other patients with AML (14). Introduction of the DS-specific
therapeutic protocols with reduced intensity of the treatment
resulted in excellent outcome (14–17).
The aim of the study was retrospective analysis of the
treatment results and genetic characteristics of pediatric ML-DS
patients treated in Poland from 2005 to 2019.
PATIENTS AND METHODS
From January 2005 to December 2019, there were 54 newly
diagnosed ML-DS patients registered in the Polish Pediatric
Leukemia and Lymphoma Study Group (PPLLSG) registry. They
were treated in 16 pediatric oncology centers in Poland. All were
eligible to the study. Inclusion criteria included age up to 18
years, diagnosis of DS and ML, and written informed consent.
Exclusion criteria comprised accompanying diseases that do not
allowML-DS therapy. Thirty-four children were treated with DS-
specific arm of the Acute Myeloid Leukemia–Berlin-Frankfurt-
Munster (AML-BFM) 2004 Registry Protocol and 20 patients
with ML-DS 2006 Protocol (Figure 1).
The last patient was enrolled in August 2019, and the last
follow-up was done in November 2019. Median observation time
was 62.7 months (range, 2.6–174.8 months). Characteristics of
the patients are presented in Table 1.
The data were collected in PPLLSG AML registry and
analyzed retrospectively.
Informed consent to participation in the studies was obtained
from guardians of all patients, in accordance with the Declaration
of Helsinki. The study was approved by the Ethics Committee of
Jagiellonian University Medical College.
From January 2005 to June 2015, 34 patients were treated
according to the DS-specific arm of the AML-BFM 2004
Interim Protocol (group I). The treatment consisted of four
chemotherapy cycles AIE (cytarabine, idarubicin, etoposide),
AI (cytarabine, idarubicin), haM (high-dose cytarabine,
mitoxantrone), HAE (high-dose cytarabine, etoposide;
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FIGURE 1 | The treatment protocols. AML-BFM 2004 Registry—group I (reduced intensity arm for children with ML-DS)—group I: AIE (cytarabine 100 mg/m2/day
[days 1–2] and 100 mg/m2 every 12 h [days 3–8], idarubicin 8 mg/m2/day [days 3, 5, and 7], and etoposide 150 mg/m2/day [days 6–8]); AI (cytarabine 500
mg/m2/day [days 1–4] and idarubicin 5 mg/m2/day [days 3 and 5]); haM (cytarabine 1 g/m2 every 12 h [days 1–3] and mitoxantrone 7 mg/m2/day [days 3–4]); HAE
(cytarabine 3 g/m2/every 12 h [days 1–3], etoposide 125 mg/m2/day [days 2–5]). Maintenance therapy lasting 1 year: thioguanine 40 mg/m2/day orally, cytarabine 40
mg/m2/day intravenously for 4 consecutive days, every 4 weeks. Intrathecal cytarabine (CNS prophylaxis)—in the each intensive treatment block, not during
maintenance therapy (in total, six aged adapted doses−20 to 40mg per dose). The cumulative doses: 29,400 mg/m2 cytarabine, 950 mg/m2 etoposide, 34 mg/m2
idarubicin, and 14 mg/m2 mitoxantrone. ML-DS 2006—group II: AIE (cytarabine 100 mg/m2/day [days 1–2] and 100 mg/m2 every 12 h [days 3–8], idarubicin 8
mg/m2/day [days 3, 5, and 7], and etoposide 150 mg/m2/day [days 6–8]); AI (cytarabine 500 mg/m2/day [days 1–4] and idarubicin 5 mg/m2/day [days 3 and 5]); haM
(cytarabine 1 g/m2 every 12 h [days 1–3] and mitoxantrone 7 mg/m2/day [days 3–4]); HA (cytarabine 3 g/m2/every 12 h [days 1–3]). Intrathecal cytarabine (CNS
prophylaxis)—at the start of each treatment block (in total, four aged adapted doses−20–40mg per dose). The cumulative doses: 27,400 mg/m2 cytarabine, 450
mg/m2 etoposide, 34 mg/m2 idarubicin, and 14 mg/m2 mitoxantrone.
additionally intrathecal cytarabine in every cycle, total six
doses), and maintenance therapy (6-thioguanine, cytarabine)
for 1 year (Figure 1). Compared to the therapy for non-DS
AML, there was reduction of doses of antracyclines (idarubicin
8 mg/m2 in AIE and 5 mg/m2 in AI instead of 12 mg/m2 and 7
mg/m2, respectively, and mitoxantrone 7 mg/m2 in haM instead
of 10 mg/m2). Median observation time in group I was 91.5
months (range, 38.3–174.8 months).
From June 2015, ML-DS Protocol was introduced. There
were additionally three children treated with ML-DS 2006 before
2015 according to individual decision of the treating center. In
total, 20 patients were treated according to the ML-DS 2006
Protocol (group II). It consisted of four chemotherapy cycles: AIE
(cytarabine, idarubicin, etoposide), AI (cytarabine, idarubicin),
haM (high-dose cytarabine, mitoxantrone), and HA (high-dose
cytarabine) (Figure 1). Intrathecal treatment with cytarabine
was given in every cycle (totally four doses). There was no
maintenance treatment. Median observation time in group II was
21.1 months (range, 2.6–89.1 months).
Cytogenetic analyses were performed in local laboratories.
Karyotype results were available in 49 patients (91%). From
2015, the status of mutation in GATA1 gene was done centrally
in the Department of Medical Genetics, Institute of Pediatrics,
Jagiellonian University Medical College, Krakow, Poland. From
each patient, DNA was isolated from 300 µL bone marrow
sample collected at diagnosis by the nucleic acid isolation system
QuickGene-Mini80 with DNA Blood kit (KURABO Industries
Ltd, Osaka, Japan). The variation inGATA1 gene coding sequence
fragments was detected by Sanger sequencing method (3500
Genetic Analyzer; Applied Biosystems, Foster City, California,
USA). Separate analyses included 2, 3, and 4 exons of the gene.
The GATA1 gene coding sequence was checked against the
reference sequence no. ENST00000376670.7. Results of GATA1
mutation status was available in 18 patients (33%).
The data that support the findings of the study are
available on request from the corresponding author.
The data are not publicly available because of privacy or
ethical restrictions.
Statistical Analysis
Descriptive statistical analysis was performed to assess patient
baseline characteristics. We used Fisher exact test or a χ2 test
(categorical variables) and Mann–Whitney U-test (continuous
variables) for analysis of clinical and laboratory data. Overall
survival (OS), event-free survival (EFS), and relapse-free survival
(RFS) were calculated using the Kaplan–Meier method. Overall
survival was defined as the time from diagnosis to death
from any cause; patients alive or lost to follow-up were
censored at the date they were last known alive. Event-
free survival was defined as the time from diagnosis to
disease progression, relapse, or death from any cause. Patients
who were alive without disease progression or relapse were
censored at the time they were last seen alive and event-
free. Relapse-free survival was defined as the time from
complete remission (CR) to disease relapse or death from any
cause. Patients who were alive without disease relapse were
censored at the time of last follow-up. For comparisons of
Kaplan–Meier curves, we used the log-rank test. Cumulative
incidence of relapse (CIR) was also counted and compared
between groups using Gray test. Statistical analysis was
performed using STATISTICA 13 software (StatSoft Polska,
Krakow, Poland).
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TABLE 1 | Characteristics of the patients.
Characteristic All patients AML-BFM 2004 interim ML-DS 2006 p
(n = 54) (n = 34) (n = 20)
n % n % n %
Sex
Male 27 50 19 56 8 60 0.29
Female 27 50 15 44 12 40
Age at diagnosis 1.9 0.7–17.4 1.9 0.7–17.4 2.2 0.9–4.9 0.26
(median, range), years
<4 50 92.6 31 91.2 19 95 0.60
>4 4 7.4 3 8.8 1 5
History of TAM
Yes 15 44.1 8 38.1 7 53.8 0.29
No 19 55.9 13 61.9 6 46.2
No data 20 13 7
FAB
M0 5 9.8 5 15.6 0 0 M7 vs. others
0.03
M1 9 17.6 8 25 1 5.3
M2 4 7.8 4 12.5 0 0
M4 1 2 1 3.1 0 0
M5 1 2 1 3.1 0 0
M6 2 3.9 1 3.1 1 5.3
M7 29 56.9 12 37.5 17 89.5
No data 3 2 1
Cytogenetics
Trisomy 21 only 21 42.8 14 45.2 7 38.9 Isolated trisomy 21 vs. others
0.65
Trisomy 8 8 16.3 5 16.1 3 16.7
Del(7) 5 10.2 4 12.9 1 5.5
Del(16) 3 6.1 3 9.7 0 0
Del(6) 3 6.1 3 9.7 0 0
Dup(7) 2 4.1 0 0 2 11.1
i(7) 2 4.1 1 3.2 1 5.5
Complex karyotype 6 12.2 4 12.9 2 11.1
No data 5 3 2
GATA1 gene mutation
Yes 7 38.9 1 20 6 46.2 0.63
No 11 61.1 4 80 7 53.2
No data 36 30 7
Congenital heart defect
Yes 24 47.1 16 51.6 8 40 0.25
No 27 52.9 15 48.4 12 60
No data 3 3 0
History before diagnosis, months
≤3 23 52.3 15 51.7 8 53.3 0.83
>3 21 47.7 14 48.3 7 46.7
No data 10 5 5
WBC at diagnosis 6.5 1.9–282 8.83 2.2–282 3.9 1.9–30.9 0.010
(median, range), × 109/L
Platelets at diagnosis 26 2–247 24 2–247 31 9–87 0.52
(median, range), × 109/L
Peripheral blasts 11 0–92 16 0–92 6.5 0–79 0.24
(median, range), %
Bone marrow blasts 30 5–91 39 10–91 25 8–59 0.015
(median, range), %
TAM, transient abnormal myelopoiesis. P-values are bolded where there are significant differences (p < 0.05) between groups.
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RESULTS
Patient Characteristics
There were 54 patients enrolled to the study, including 27
girls and 27 boys. The median age at diagnosis was 1.9 years
(range, 0.7–17.4 years). Fifty children were younger than 4 years,
and four patients were older (4.01, 4.9, 10.5, and 17.4 years).
There were no significant differences between groups I and II
concerning sex and age. Median number of white blood cells
at diagnosis was 6.5 × 109/L (range, 1.9–282 × 109/L). It was
significantly higher in group I (median, 8.83; range, 2.2–282 ×
109/L) than in group II (median, 3.9; range, 1.9–30.9 × 109/L;
p = 0.01). Median percentage of peripheral blasts in the whole
cohort was 11% (range, 0%−92%), with no significant differences
between the groups. The percentage of bone marrow blasts was
significantly higher in group I (median, 39%; range, 10–92%)
compared to group II (median, 25%; range, 8–59%). Detailed
characteristics are presented in Table 1.
Treatment Outcome
Forty-nine patients (90.7%) achieved CR (30/34 patients in group
I and 19/20 patients in group II). Five patients (9.3%) died
of toxicities before CR (0.5–2.2 months from diagnosis). The
deaths were caused by infections in course of aplasia (two due
to sepsis, two due to pneumonia, one due to typhlitis). Forty-
five patients (83%) remain in continuous CR (26/34 in period
I and 19/20 in period II). There were three deaths in CR (all
in group I), two patients died of pneumonia (1 and 7.4 months
after diagnosis), and one patient because of cardiac tamponade
(1.4 months from diagnosis). In total, eight deaths from toxicities
occurred (14.8%): seven in group I (20.6%) and one in group
II (5%) (p = 0.078). The only one relapse in the whole cohort
occurred in the patient from group I, diagnosed of ML-DS at age
of 10.5 years. His karyotype revealed isolated chromosome 21
trisomy; GATA1 mutation was excluded. No additional genetic
changes were found in molecular analysis. Leukocyte count at
diagnosis was 74.8 × 109/L, with 90% of blasts, much higher
than median in the analyzed cohort. The proportion of blast
in the bone marrow (91%) was also much higher than median
value in the whole group. The patient responded well to the
first-line chemotherapy. Relapse occurred 21.7 months from
CR. The patient was successfully treated with IdaFLA cycle
followed by allogenic hematopoietic stem cell transplantation
(HSCT) from the matched sibling donor. Conditioning with
fludarabine, melphalan, and total body irradiation was used.
The patient received cyclosporine and methotrexate as graft-
vs.-host disease (GvHD) prophylaxis. Chronic GvHD with skin
involvement occurred in the patient. He remains in the second
CR for 33 months.
Probabilities of 5-year OS, EFS, and RFS in the whole analyzed
group were 0.85± 0.05, 0.83± 0.05, and 0.97± 0.03, respectively
(Figure 2). There was a trend toward an improved OS and EFS
in group II compared to group I (OS and EFS 0.95 ± 0.05 vs.
0.79 ± 0.07, p = 0.14, and 0.95 ± 0.05 vs. 0.76 ± 0.07, p =
0.12, respectively; Figures 3, 4). There was one relapse in group I
and no relapses in group II. In the whole cohort, 5-year CIR was
0.0286: in group I, 0.037; and in group II, 0. The difference was
not statistically significant (p= 0.58).
Genetic Analyses
The GATA1 gene analysis was available in 18 patients, mainly
from group II (n = 13). Analysis of GATA1 gene was not done
in the patients who died. Mutation was found in 7 of 18 patients
(38.9%). The group of patients with GATA1 gene mutation
did not differ from the group without mutation regarding
percentages of blasts at diagnosis and age. There were only two
patients older than 4 years with known GATA1 status, both
without mutation. There were no events in the patients with
GATA1 gene mutation and one relapse in the group without
GATA1 gene mutation.
Results of the cytogenetic analysis were available in
49 patients. There were no significant differences in OS
nor EFS depending on karyotype (isolated trisomy 21
vs. additional genetic changes). Presence of trisomy 8;
chromosome 7, 6, or 16 deletion; or complex karyotype
did not influence significant probabilities of OS and EFS
(Table 2). Detailed genetic characteristics are presented
in Table 3.
Analysis of Medical History Before
Diagnosis
Data concerning medical history from the first symptoms to the
diagnosis of ML-DS were available in 34 patients. No significant
differences in OS or EFS were found depending on the length of
the history (<3 vs. >3 months; Table 2).
In 15 patients (44% from 34 with available data
concerning TAM), ML-DS was preceded by TAM. Treatment
results were similar in the patients with and without
TAM (Table 2).
Congenital heart defect was detected in 24 patients (58.5%
of 41 children with available data). In one of those patients
with history of atrioventricular canal correction before
AML diagnosis, severe cardiac insufficiency occurred during
induction therapy. The patient needed second cardiac surgery
(closure of secundum atrial septal defect, mitral, and tricuspid
valvuloplasty). After stabilization of the general condition, the
patient continued chemotherapy and stays in remission. One
patient with congenital heart defect died during the treatment
because of cardiac tamponade. There were no differences in
survival between patients with and without congenital hearts
defect (Table 2).
DISCUSSION
Introduction of the ML-DS–specific treatment protocols with
reduced intensity of chemotherapy improved the outcome in
that special group of patients (14–17). It resulted in reduction
of the risk of toxicities and allowed to maintain excellent
treatment response at the same time (14–17). In this study,
we analyzed retrospectively the treatment outcome in the
two consecutive treatment protocols specific for ML-DS. In
AML-BFM 2004 Interim Protocol, the DS-specific arm had
reduced antracyclines doses compared to standard treatment,
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FIGURE 2 | Probability of overall, event-free, relapse-free survival in all analyzed patients with ML-DS. ML-DS, myeloid leukemia of Down syndrome; OS, overall
survival; EFS, event-free survival; RFS, relapse-free survival.
FIGURE 3 | Comparison of overall survival in patients with ML-DS treated with AML-BFM 2004 Interim Protocol and ML-DS 2006 Protocol. ML-DS, myeloid leukemia
of Down syndrome; OS, overall survival.
and intrathecal therapy and central nervous system (CNS)
irradiation were omitted in the maintenance treatment. In the
ML-DS 2006 Protocol, further reduction of chemotherapy was
introduced. There was no maintenance treatment; all doses of
etoposide were omitted in the last cycle of chemotherapy, and
there were four doses of intrathecal cytarabine instead of six
in the previous protocol. The treatment outcome in the whole
analyzed group of patients (5-year OS 0.85 ± 0.05 and EFS
0.83 ± 0.05) is comparable to the results recently described
by large pediatric oncology groups: Children Oncology Group
(COG) with 5-year OS 93.0% and EFS 89.9% (15) joined the
Nordic Society for Pediatric Hematology and Oncology, Dutch
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FIGURE 4 | Comparison of event-free survival in patients with ML-DS treated with AML-BFM 2004 Interim Protocol and ML-DS 2006 Protocol. ML-DS, myeloid
leukemia of Down syndrome; EFS, event-free survival.
Childhood Oncology Group, and the AML-BFM study group
with OS 89 ± 3% and EFS 87 ± 3% (16), as well as Japanese
Pediatric Leukemia/Lymphoma Study Group with OS 87.5 ±
3.9% and EFS 83.3± 4.4% (17).
In the analyzed group of patients, reduction of the
chemotherapy intensity in the ML-DS 2006 Protocol compared
to AML-BFM 2004 Interim DS-specific arm resulted in
improvement of survival rates (OS 0.95 ± 0.05 vs. 0.79 ±
0.07, p = 0.14, and EFS 0.95 ± 0.05 vs. 0.76 ± 0.07, p
= 0.12), but the differences were not statistically significant.
In group I, the treatment-related mortality (TRM) of 20.6%
was much higher than described by other authors (1.5–
4.9%) (15, 16, 18). Proportion of deaths from toxicities
decreased to 5.0% in group II; however, the differences were
not statistically significant. Decrease of the TRM probably
resulted mainly from improvement of supportive treatment and
experience of the treating centers, as almost all deaths from
toxicities in group I occurred after the first chemotherapy cycle
(reduction of chemotherapy concerned the last chemotherapy
cycle and maintenance therapy). Reduction of the intensity of
chemotherapy did not affect the treatment efficacy. There were
no relapses in group II, compared to one relapse in group I. The
5-year CIR in the whole cohort was 3%. The result is excellent
compared to other studies with the 5-year CIR of 6–10.0% (15,
16). Despite generally poor prognosis in relapsed ML-DS (OS,
25.9–34.3%) (15, 19), our patient was treated successfully with
IdaFLA chemotherapy followed by HSCT.
In order to optimize the treatment of ML-DS, many efforts are
made to find prognostic factors. Uffmann et al. (16) performed
multivariate analysis and revealed that poor early response and
the gain of chromosome 8 were independent prognostic factors.
In the recent study of COG, the only one significant predictor
of outcome was MRD on day 28 of induction (15). According
to the Japanese Pediatric Leukemia/Lymphoma Study Group
AML-D05 study, age at diagnosis of <2 years was a significant
favorable prognostic factor for risk of relapse (17). Retrospective
international study including 451 ML-DS patients from 13
collaborative study groups participating in the International-
BFM AML Study Group revealed that patients with normal
karyotype had a higher CIR (21 ± 4%) than cases with an
aberrant karyotype (n= 255) with a CIR of 9% (±2%) (20).
In our study, no significant prognostic factor was found
probably because of low number of patients in the subgroups.
Efforts are made to define mechanisms of leukemic
transformation from TAM to ML-DS. In the recent study,
Labuhn et al. (21) showed that trisomy 21 and GATA1 mutation
are sufficient for the development of TAM. They identified
transforming hotspot mutation in myeloid cytokine receptor
CSF2RB. Using a multiplex CRISPR/Cas9 screen in an in
vivo murine TAM model, they found that loss of 18 from
22 tested recurrently mutated ML-DS genes led to leukemia
phenotypically, genetically, and transcriptionally similar to
ML-DS (21).
The most frequent chromosomal alterations associated with
ML-DS are as follows: dup(1q), del(6q), del(7p), dup(7q), +8,
+11, del(16q), and +21 (22). In our study among 49 patients
with cytogenetic analysis, 43% had isolated trisomy 21. The most
frequent numerical abnormality involved trisomy 8 (16.3%);
structural abnormalities comprised del(7) (10.2%), del(6) (6.1%),
del(16q) (6.1%), dup(7) (4%), isochromosome 7 (4%) (Table 3).
Other abnormalities were found in the single patients (Table 3).
Complex karyotype was revealed in 12.2% of patients.
The GATA1 gene analysis became available for most ML-
DS patients from 2015. Status of the gene was analyzed in
18 patients. Surprisingly, mutation was found in only 38% of
those children, whereas the prevalence of GATA1 mutation in
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TABLE 2 | Treatment outcome in the defined groups of the patients.
n Deaths OS p Events EFS p Relapse
Total 54 8 85.5 9 85.5 1
Sex 0.46 0.30
Male 27 3 0.89 3 0.76 1
Female 27 5 0.81 6 0.89 0
Age at diagnosis, years 0.39 0.72
<4 50 8 0.84 8 0.84 0
>4 4 0 1.0 1 0.67 1
History of TAM 0.41 0.41
Yes 15 1 0.93 1 0.93 0
No 19 3 0.84 3 0.84 0
No data 20
Cytogenetics
Trisomy 21 only 0.72 0.54
Yes 21 4 0.84 5 0.80 1
No 28 3 0.87 3 0.87 0
Trisomy 8 0.82 0.74
Yes 8 1 0.87 1 0.87 0
No 41 6 0.85 7 0.82 1
del(7) 0.66 0.77
Yes 5 1 0.80 1 0.80 0
No 44 6 0.86 7 0.83 1
del(6) 0.47 0.41
Yes 3 0 1.0 0 1.0 0
No 46 7 0.85 8 0.82 1
del(16) 0.33 0.42
Yes 3 1 0.67 1 0.67 0
No 46 6 0.87 7 0.84 1
Complex karyotype 0.29 0.26
Yes 6 0 1.0 0 1.0 0
No 43 7 0.84 8 0.81 1
No data 5
Congenital heart defect 0.30 0.51
Yes 24 2 0.92 3 0.87 1
No 27 5 0.81 5 0.81 0
No data 3
History before diagnosis, months 0.70 0.45
≤3 23 3 0.87 4 0.81 1
>3 21 2 0.90 2 0.90 0
No data 10
EFS, probability of event-free survival; OS, probability of overall survival; TAM, transient abnormal myelopoiesis.
other studies was 85–89% (15, 16). It could not be explained
by low percentage of blasts at diagnosis because it was similar
in the group with and without mutation. There could be some
false-negative results as the Sanger sequencing used to detect
GATA1 mutation has limited sensitivity. Finally, the group of
patients who had GATA1 analysis was small and could be
not representative.
No significant influence of the genetic features on the
treatment outcome was revealed in the analyzed cohort.
In conclusion, the study confirms that reduced intensity
protocols are very effective in ML-DS patients. The main cause
of deaths remained toxicities (there were no deaths from the
disease); however, systematic decrease of the TRM was noticed
in the analyzed group.
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TABLE 3 | Patients with additional genetic abnormalities.
Cytogenetics Age, FAB Outcome Follow-up, months
years
47,XX,+21,del(16) 1–2 7 Death in CR 0.90
47,XY,der(1)add(1)(p?36.3)add(1)(q44),+21c[5] /48,XY,+9,+21c[1]/47,XY,+21c[24] 3–4 0 CCR 85.4
47,XX, +21, add(5),del(1)(q32),del(9)(q13-22),del (12)(q15-24.1) 2–3 7 CCR 32.7
47,XX,dic(5;7)(p12;p12),+21c[4]/47,XX,+21c[10] 1–2 7 CCR 20.7
48-50,XY,+8[10],+8[10],t(18;21)(q10;q10)c, +der(18;21) (q10;q10),+21,+21[2][cp20] 1–2 7 CCR 15.6
48,XY,+8,+21 1–2 1 Early death in aplasia 2.2
47,XY, +21 [3]/48, XY, +8, +21 [2] 2–3 2 CCR 154.4
47,XX,der(5)t(5;15)(q34;q22)+21[7]/47,XX+21[13] 4–5 7 CCR 21.3
48–50,XX,dup(7)(p13p22),+r(21)(pII.2q22.1) × 2–4 2–3 7 CCR 8.1
48,XX, inv(5)(p15q33)del(5)(p15.3),r(7)(p?)del(7) (q22), +21c,+21[10]/47,XX,+21c[15] 2–3 7 CCR 62.7
48,XY,del(6)(q13q22),+11,der(17)t(1;17)(p?;p13), +21c[2]/47,XY,+21c[28] 2–3 7 CCR 38.3
47,XY,r(7)dup(7)(q331q?32),+21c[17]/47,XY+21c[6] 1–2 7 CCR 9.2
50,XY,+19,+20,+21c,+22 [2]/47,XY,+21c[18] 1–2 nd CCR 66.0
47,XX,+21c,del(6)(q23) (20) 1–2 0 CCR 79.3
48,XX,+8[11],+21[16][cp18]/46,XX[2] 1–2 7 CCR 62.7
47,XY,del(11)(q23),+21c[2]/49,XY,+8,del(11)(q23),+15,+21c[6]/47,XY,+21c[15] 2–3 7 CCR 3.5
47,XX,+21; del(6)(q21qter),del(12)(p12pter),del(5)(q4pter), 4–5 1 CCR 152.1
trisomy 18, trisomy 19, trisomy 22, hyperdiploidy in 25% of metaphases
47,XX, del(7)(q32),+21c; 47XX, +21 2–3 0 Early death in aplasia 0.6
47,XX, del(16)(q12q22), +21c[11] <1 7 CCR 120.6
48,XX,+8+21c[5]/47,XX,+21c[12]/46,XX[3]′ 2–3 1 CCR 115.8
47,XY,+21c[3] 2–3 7 CCR 18.1
FISH—trisomy 8 in 9% of 200 interphase nuclei
47,XY,+ 21, i(7q) 1–2 nd CCR 94.3
47,XX, i(7)(q10), +21c[18]/47,XX, +21c[2] 1–2 nd CCR 8.8
47,XY,+21c[18]/46, XY [2] FISH del(7q22)(7q35) 2–3 7 CCR 95.4
47,XX, del(16)(q13),t21c [2]/47,XX,+21c 2–3 7 CCR 93.5
47,XY,+21, FISH trisomy 8 1–2 5 CCR 80.5
47,XX,+21,t(7;21) 2–3 7 CCR 89.7
47,XY,+21,der(7)t(7;11) 2–3 7 CCR 80.6
CCR, continuous complete remission; CR, complete remission; nd, no data.
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